Updated:
Outset Medical
Outset Medical was founded in 2003 and reshaped under CEO Leslie Trigg, who joined in 2014 and drove the company toward a 2020 Nasdaq IPO (per the firm's...
Outset Medical
Outset Medical was founded in 2003 and reshaped under CEO Leslie Trigg, who joined in 2014 and drove the company toward a 2020 Nasdaq IPO (per the firm's SEC filings, 2020). The company was built to address the capital-intensity and complexity of traditional dialysis — a procedure long dominated by Fresenius and Baxter machines that require dedicated plumbing and extensive training. Trigg repositioned the company as a technology-first medical-device platform, relocating headquarters to San Jose to anchor engineering talent. The firm's sole commercial product, Tablo, targets the roughly 500,000 U.S. patients on chronic dialysis, with specific penetration into the acute-care hospital market and the growing home-dialysis segment. Tablo integrates water purification, dialysate production, and the monitoring interface into one wheeled console. The revenue split follows a consumables-driven model: hospitals purchase or lease the capital equipment, then commit to a recurring stream of single-use cartridges and disposables. Outset also sells software-as-a-service through TabloHub, a cloud portal that gives nephrologists real-time treatment data and inventory management. Geographic coverage is concentrated in the United States, and the firm has described international expansion as an opportunistic priority rather than a near-term growth lever (per the firm's annual report, 2023). Trigg oversees a team of roughly 500 professionals as of early 2024, primarily based at the San Jose headquarters with a commercial footprint distributed across U.S. territories. The firm's manufacturing operations are concentrated in Tijuana, Mexico, where it invested in a dedicated production line to scale cartridge output and improve gross margins. Outset operates a single public-company entity with no separate philanthropic foundation, adjacent real-asset arms, or club-investment structures. In November 2023, the firm announced a restructuring plan reducing its workforce by approximately 10% and refocusing commercial efforts on acute-care accounts, where Tablo utilization rates are highest (per a public SEC filing, November 2023). The key structural differentiator is Outset's regulatory clearance as the first hemodialysis machine to receive FDA approval for use in the home setting with tap-water input, granted in 2020. This eliminated the requirement for a pre-installed water-purification system, the single largest barrier to in-home dialysis adoption in the U.S. The company is not a family office or fund — it is a publicly traded medical-device manufacturer — but it competes in a dialysis-services ecosystem where the major payors, including Fresenius and DaVita, are vertically integrated care providers, making Outset an independent equipment supplier in a consolidated market.
General information
Firm type
Asset Manager
Year founded
2003
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Jose
Corporate office
San Jose, CA, United States
Principals
Leslie Trigg
Chief Executive Officer
Sector focus
Frequently asked questions
What does Outset Medical manufacture?
Outset Medical manufactures the Tablo Hemodialysis System, a single-console device that integrates water purification, dialysate production, and patient monitoring. It received FDA clearance in 2014 for acute and chronic care settings and, in 2020, became the first hemodialysis machine cleared for home use without requiring a dedicated pre-installed water-purification system. The device is designed to reduce the infrastructure burden and staff training required for traditional dialysis machines.
How does Outset Medical generate revenue?
Outset Medical operates a razor-and-blade revenue model. It sells or leases the Tablo console to hospitals, dialysis providers, and increasingly home-dialysis programs, then earns recurring revenue from single-use disposables, including integrated cartridges and tubing sets, required for each treatment. The firm also sells a cloud-based software portal, TabloHub, that provides real-time treatment analytics and fleet-management data to clinicians and administrators.
Who runs investment decisions at Outset Medical?
Outset Medical is a publicly traded medical-device company, not an investment firm or family office. Capital-allocation and strategic decisions are made by the board of directors and executive management, led by CEO Leslie Trigg. Investment decisions — such as capital raises, manufacturing scale-ups, and restructuring actions — are disclosed through SEC filings and earnings calls. The firm does not manage outside capital, co-investor pools, or third-party discretionary funds.
What is Outset Medical's competitive position relative to Fresenius and DaVita?
Fresenius and DaVita are vertically integrated dialysis providers that own clinics, employ nephrologists, and manufacture their own equipment. Outset Medical is an independent equipment supplier — it does not operate clinics or employ physicians. Its competitive pitch is a portable, simplified console that hospitals can deploy without the plumbing infrastructure traditionally required, making it particularly suited for acute-care settings and home-dialysis programs where space and capital budgets are constrained.
Does Outset Medical participate in fund commitments or direct deals?
No. Outset Medical is a single-entity operating company publicly listed on Nasdaq under the ticker OM. It does not make fund investments, direct venture deals, co-investments alongside external managers, or maintain any investment-vehicle structure. All capital raised through public equity offerings or debt facilities has been deployed into the company's own operations, R&D, and manufacturing capacity.
What investment stages or sectors does Outset Medical participate in?
Outset Medical does not participate in any investment stage or sector as a capital allocator. The firm is strictly an operating company in the medical-device and healthcare-technology sector, focused on designing, manufacturing, and commercializing hemodialysis equipment and related software. It has no venture arm, corporate-venture unit, or strategic-investment portfolio.
Where does Outset Medical manufacture its products?
The final assembly and manufacturing of the Tablo console and its associated single-use disposables are concentrated in Tijuana, Mexico, where Outset Medical has invested in a dedicated production line. The San Jose, California headquarters houses engineering, regulatory, and corporate functions. The firm has publicly stated that its Tijuana manufacturing scale-up was a key component of its path to gross-margin improvement.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: